Nilotinib - Novartis Pharmaceuticals Corporation

Drug Profile

Nilotinib - Novartis Pharmaceuticals Corporation

Alternative Names: AMN-107; Nilotinib-nanoparticle-formulation-Xspray-Pharma; RightSize-nilotinib; Tasigna

Latest Information Update: 15 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Developer Dana-Farber Cancer Institute; Hospital for Special Surgery; Novartis Pharmaceuticals Corporation; Seoul St. Mary's Hospital; University Health Network of Toronto
  • Class Antineoplastics; Benzamides; Imidazoles; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours; Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Malignant melanoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Acute myeloid leukaemia
  • No development reported Gastrointestinal stromal tumours; Systemic scleroderma
  • Discontinued Eosinophilia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 14 Jun 2018 Interim efficacy and adverse events data from a phase II ENESTfreedom trial in Chronic myeloid leukaemia presented at the 23rd Congress of the European Haematology Association (EHA-2018)
  • 14 Jun 2018 Interim efficacy and adverse events data from a phase II ENESTop trial in Chronic myeloid leukaemia presented at the 23rd Congress of the European Haematology Association (EHA-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top